The Primacy of Public Health Considerations in Defining Poor Quality Medicines

Paul Newton and colleagues argue that public health, and not intellectual property or trade issues, should be the prime consideration in defining and combating counterfeit medicines, and that the World Health Organization (WHO) should take a more prominent role.

Detalles Bibliográficos
Autores principales: Newton, Paul N., Amin, Abdinasir A., Bird, Chris, Passmore, Phillip, Dukes, Graham, Tomson, Göran, Simons, Bright, Bate, Roger, Guerin, Philippe J., White, Nicholas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Essay
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232210/
https://www.ncbi.nlm.nih.gov/pubmed/22162953
http://dx.doi.org/10.1371/journal.pmed.1001139
_version_ 1782218335302189056
author Newton, Paul N.
Amin, Abdinasir A.
Bird, Chris
Passmore, Phillip
Dukes, Graham
Tomson, Göran
Simons, Bright
Bate, Roger
Guerin, Philippe J.
White, Nicholas J.
author_facet Newton, Paul N.
Amin, Abdinasir A.
Bird, Chris
Passmore, Phillip
Dukes, Graham
Tomson, Göran
Simons, Bright
Bate, Roger
Guerin, Philippe J.
White, Nicholas J.
author_sort Newton, Paul N.
collection PubMed
description Paul Newton and colleagues argue that public health, and not intellectual property or trade issues, should be the prime consideration in defining and combating counterfeit medicines, and that the World Health Organization (WHO) should take a more prominent role.
format Online
Article
Text
id pubmed-3232210
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-32322102011-12-09 The Primacy of Public Health Considerations in Defining Poor Quality Medicines Newton, Paul N. Amin, Abdinasir A. Bird, Chris Passmore, Phillip Dukes, Graham Tomson, Göran Simons, Bright Bate, Roger Guerin, Philippe J. White, Nicholas J. PLoS Med Essay Paul Newton and colleagues argue that public health, and not intellectual property or trade issues, should be the prime consideration in defining and combating counterfeit medicines, and that the World Health Organization (WHO) should take a more prominent role. Public Library of Science 2011-12-06 /pmc/articles/PMC3232210/ /pubmed/22162953 http://dx.doi.org/10.1371/journal.pmed.1001139 Text en Newton et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Essay
Newton, Paul N.
Amin, Abdinasir A.
Bird, Chris
Passmore, Phillip
Dukes, Graham
Tomson, Göran
Simons, Bright
Bate, Roger
Guerin, Philippe J.
White, Nicholas J.
The Primacy of Public Health Considerations in Defining Poor Quality Medicines
title The Primacy of Public Health Considerations in Defining Poor Quality Medicines
title_full The Primacy of Public Health Considerations in Defining Poor Quality Medicines
title_fullStr The Primacy of Public Health Considerations in Defining Poor Quality Medicines
title_full_unstemmed The Primacy of Public Health Considerations in Defining Poor Quality Medicines
title_short The Primacy of Public Health Considerations in Defining Poor Quality Medicines
title_sort primacy of public health considerations in defining poor quality medicines
topic Essay
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232210/
https://www.ncbi.nlm.nih.gov/pubmed/22162953
http://dx.doi.org/10.1371/journal.pmed.1001139
work_keys_str_mv AT newtonpauln theprimacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT aminabdinasira theprimacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT birdchris theprimacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT passmorephillip theprimacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT dukesgraham theprimacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT tomsongoran theprimacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT simonsbright theprimacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT bateroger theprimacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT guerinphilippej theprimacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT whitenicholasj theprimacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT newtonpauln primacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT aminabdinasira primacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT birdchris primacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT passmorephillip primacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT dukesgraham primacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT tomsongoran primacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT simonsbright primacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT bateroger primacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT guerinphilippej primacyofpublichealthconsiderationsindefiningpoorqualitymedicines
AT whitenicholasj primacyofpublichealthconsiderationsindefiningpoorqualitymedicines

Ejemplares similares